Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238925 | 0.90 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL7558991 | 0.89 | DPP4 (0.51) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| Hydrochloric Acid SCHEMBL5234681 | 0.88 | DPP4 (0.50) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL5231871 | 0.86 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL5235297 | 0.83 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL5239103 | 0.83 | DPP4 (0.41) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL6107420 | 0.82 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL5237699 | 0.80 | DPP4 (0.44) | GABRA1GABRG2GABRB3GABRA5DPP4 | |
| SCHEMBL5231873 | 0.80 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5PTGER1 | |
| SCHEMBL5233155 | 0.80 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA5PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | GABRA1 3124/4885GABRG2 3321/4885GABRB3 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.